# Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

> **NCT06724042** · PHASE1 · NOT_YET_RECRUITING · sponsor: **InSilico Medicine Hong Kong Limited** · enrollment: 159 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Solid Tumor
- Advanced and/or Metastatic Solid Tumors

## Interventions

- **DRUG:** ISM5939
- **DRUG:** Cisplatin
- **DRUG:** Docetaxel
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06724042
- **Lead sponsor:** InSilico Medicine Hong Kong Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2029-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 159 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06724042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06724042, "Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06724042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*